1. Home
  2. CODA vs ALXO Comparison

CODA vs ALXO Comparison

Compare CODA & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CODA
  • ALXO
  • Stock Information
  • Founded
  • CODA 1994
  • ALXO 2015
  • Country
  • CODA United States
  • ALXO United States
  • Employees
  • CODA N/A
  • ALXO N/A
  • Industry
  • CODA Industrial Machinery/Components
  • ALXO Biotechnology: Pharmaceutical Preparations
  • Sector
  • CODA Industrials
  • ALXO Health Care
  • Exchange
  • CODA Nasdaq
  • ALXO Nasdaq
  • Market Cap
  • CODA 92.5M
  • ALXO 28.3M
  • IPO Year
  • CODA N/A
  • ALXO 2020
  • Fundamental
  • Price
  • CODA $6.77
  • ALXO $0.43
  • Analyst Decision
  • CODA Strong Buy
  • ALXO Strong Buy
  • Analyst Count
  • CODA 1
  • ALXO 6
  • Target Price
  • CODA $11.00
  • ALXO $4.14
  • AVG Volume (30 Days)
  • CODA 46.1K
  • ALXO 522.3K
  • Earning Date
  • CODA 06-11-2025
  • ALXO 05-08-2025
  • Dividend Yield
  • CODA N/A
  • ALXO N/A
  • EPS Growth
  • CODA 61.24
  • ALXO N/A
  • EPS
  • CODA 0.34
  • ALXO N/A
  • Revenue
  • CODA $21,064,685.00
  • ALXO N/A
  • Revenue This Year
  • CODA $11.64
  • ALXO N/A
  • Revenue Next Year
  • CODA $14.53
  • ALXO N/A
  • P/E Ratio
  • CODA $19.42
  • ALXO N/A
  • Revenue Growth
  • CODA 15.63
  • ALXO N/A
  • 52 Week Low
  • CODA $5.76
  • ALXO $0.44
  • 52 Week High
  • CODA $9.89
  • ALXO $17.50
  • Technical
  • Relative Strength Index (RSI)
  • CODA 54.68
  • ALXO 36.09
  • Support Level
  • CODA $6.41
  • ALXO $0.44
  • Resistance Level
  • CODA $7.09
  • ALXO $0.55
  • Average True Range (ATR)
  • CODA 0.36
  • ALXO 0.05
  • MACD
  • CODA 0.04
  • ALXO 0.00
  • Stochastic Oscillator
  • CODA 65.03
  • ALXO 13.29

About CODA Coda Octopus Group Inc. Common stock

Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. It operates in two segments: Marine Technology Business and Marine Engineering Business. The Technology Business develops proprietary solutions for both the commercial and defense subsea market. Its solutions include hardware and software for Geophysical Systems, Motion & Positioning Systems, and Real-Time Volumetric Imaging Sonar. The Engineering Business segment provides engineering services to a range of clients in the defense markets. Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Marine Technology Business segment.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: